A November 2018 article in the BMJ reported a study concluding what many lawyers have known for a long time: patients who use sodium-glucose cotransporter 2 (SGLT2) inhibitors are twice at risk of having lower limb amputations than other diabetes medications. The scientists also reported that SGLT2 inhibitors are also linked to diabetic ketoacidosis.
What Are SGLT2 Inhibitors?
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are medications that lower blood sugar in adults who have type 2 diabetes. They are used to complement diet and exercise. SGLT2 inhibitors may be available as a single-ingredient product or combined with other diabetic medications including metformin. They reduce the amount of glucose being absorbed by the body through the kidneys. This helps to reduce blood sugar by removing excess glucose through urine.